Education
About Us
Working with TipRanks
Follow Us
Palatin Technologies (PTN)
XASE:PTN
Top Page
Palatin Technologies
(NYSE MKT:PTN)
Select Model
Select Model
Rating:49Neutral
Price Target:
$23.00
▲(43.30% Upside)
Action:ReiteratedDate:02/18/26
The score is held back primarily by weak financial performance (ongoing losses and significant, persistent cash burn despite low leverage). The earnings call improves the outlook via strengthened liquidity and clear near-term development milestones, while technicals are mixed and valuation support is limited due to negative earnings and no dividend.
Positive Factors
Low Leverage / Balance Sheet
Extremely low reported debt materially reduces near-term refinancing and interest-rate risk, preserving management optionality to fund R&D or pursue licensing. For a small biotech, minimal leverage limits downside from cash-flow volatility and increases strategic flexibility over the next 2–6 months.
Strengthened Liquidity / Runway
A successful $18.2M financing that increased cash to ~$14.5M and extended runway materially de-risks near-term execution: management can advance IND filings and Phase I starts for two MC4R programs without immediate dilution. This funding supports milestone delivery and preserves upside from upcoming data readouts.
Focused Pipeline Strategy
Concentrating on rare/ genetic obesity indications and aiming for improved tolerability and reduced off-target effects creates a durable strategic niche. If clinical differentiation holds, the program could command premium partner interest and combination optionality with GLP-1 therapies, improving commercial prospects.
Negative Factors
Persistent Cash Burn
Sustained negative operating and free cash flow of roughly -$16M TTM indicates the business cannot self-fund development. Persistent burn raises dilution and financing risk beyond existing runway, forcing reliance on future warrant exercise, offerings, or partner payments to sustain multi-year clinical programs.
Minimal and Volatile Revenue Base
Revenue is small, non-recurring and highly lumpy, driven by royalties/milestones rather than stable product sales. This structural volatility undermines predictable funding, increases dependence on partner execution for cash inflows, and complicates multi-year planning for R&D and commercialization activities.
Clinical and Competitive Risk
The MC4R programs must prove tolerability and differentiation versus existing obesity therapies. Failure to show clear safety/efficacy advantages would limit adoption, require combination strategies, or reduce partner interest, heightening the probability of delayed or diminished commercial returns over the medium term.
Palatin Technologies (PTN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$38.07M
Dividend YieldN/A
Average Volume (3M)2.99K
Price to Earnings (P/E)―
Beta (1Y)-0.42
Revenue Growth271.10%
EPS Growth87.20%
CountryUS
Employees30
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.86
Shares Outstanding1,772,199
10 Day Avg. Volume2,746
30 Day Avg. Volume2,993
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.18
Enterprise Value/Market Cap14.41
Enterprise Value/Revenue61.18
Enterprise Value/Gross Profit61.64
Enterprise Value/Ebitda-57.34
Forecast
1Y Price Target
$50.00Price Target Upside211.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.45
Revenue Forecast (FY)$9.68M
Palatin Technologies Business Overview & Revenue Model
Company DescriptionPalatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
How the Company Makes MoneyPalatin makes money primarily through partnered commercialization and licensing economics tied to its drug assets rather than through large-scale direct product sales. Key revenue streams typically include: (1) collaboration and license revenue (e.g., upfront license fees, development/regulatory milestone payments, and commercialization milestones) earned when partners advance licensed products; (2) royalties on net sales of products commercialized by partners (historically including royalties related to Vyleesi/bremelanotide sales by the commercial rights holder); and (3) contract/other collaboration payments where applicable (e.g., reimbursement or research funding under a collaboration agreement). Palatin’s earnings are therefore significantly influenced by partner performance (launch execution and sales levels), achievement of clinical/regulatory milestones, and the pace of out-licensing or partnering for pipeline programs. null
Palatin Technologies Earnings Call Summary
Earnings Call Date:Feb 17, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:May 19, 2026
Earnings Call Sentiment Positive
The call highlighted substantial strategic and financial progress: a successful $18.2M public offering (net $16.9M), regained NYSE American listing, a $14.5M cash balance with a runway beyond March 31, 2027, and clear IND/Phase I timelines for two MC4R programs with sufficient cash to execute Phase I. Offsetting these positives are materially higher operating expenses and a larger net loss versus the prior year, minimal current commercial revenue, a decline in other income, and remaining uncertainties around warrant exercises and clinical differentiation. On balance, the financing and clear development milestones materially de-risk near-term execution, while the company still faces typical biotech development and competitive risks.Q2-2026 Updates
Positive Updates
Successful Financing and Strengthened Balance Sheet
Completed an upsized underwritten public offering on November 12, 2025 with gross proceeds of $18.2M and net proceeds of approximately $16.9M; offering included ~2.8M shares/prefunded warrants and Series J/K warrants. The financings restored NYSE American compliance and resumed trading under symbol PTN.
Significant Cash Increase and Extended Runway
Cash and cash equivalents were $14.5M as of December 31, 2025, up from $1.3M at September 30, 2025 (increase of ~1,015%) and $2.6M at June 30, 2025 (increase of ~458%). Management expects cash runway to extend beyond the quarter ending March 31, 2027.
Pipeline Advancement — IND and Phase I Timelines
Lead oral MC4R agonist PL-7737 remains on track for IND submission and initiation of Phase I SAD/MAD in H1 2026. Next-generation once-weekly peptide MC4R agonist targeting IND in H2 2026.
Sufficient Funding to Execute Early Clinical Plan
Company states it has sufficient cash to advance both the oral small molecule and long-acting peptide through Phase I SAD/MAD. Oral small molecule data expected by year-end 2026; long-acting peptide data expected in first half of 2027.
Monetization of Non-Core Asset
Executed sublicensing of PL9643 (MC1R agonist for dry eye disease) to Altanispac Labs in January 2026, resulting in approximately $3.8M in upfront consideration (noncash debt cancellation) and retained potential milestone/royalty upside; $3.8M to be recognized as license revenue in the quarter ending March 31, 2026.
Focused Strategic Positioning in Rare/Genetic Obesity
Clear strategic focus on rare neuroendocrine obesity disorders (hypothalamic obesity and Prader-Willi syndrome) with an emphasis on differentiated product profiles (improved tolerability, reduced GI side effects, minimized off-target hyperpigmentation) and optionality for combination with GLP-1 therapies.
Operational Consistency in Cash Burn
Net cash used in operations was $4.8M for the quarter, consistent with the same quarter last year, indicating predictable near-term operating cash burn.
Negative Updates
Increased Operating Expenses
Total operating expenses rose to $7.4M for the quarter ended December 31, 2025 versus $2.6M in the prior-year period — an increase of approximately 185% year-over-year — driven by higher investment in MC4R obesity programs, increased compensation and professional fees, and the absence of a prior-year gain on the sale of Vyleesi.
Larger Net Loss
Net loss widened to $7.3M ($2.86 per share) for the quarter versus a net loss of $2.4M ($5.92 per share) in the comparable period last year — net loss increased ~204% in dollar terms, while loss per share decreased ~51.7% reflecting dilution from the financing.
Minimal Current Revenue
Reported revenue for the quarter was $116K (cost reimbursements under a collaboration) versus $0 in the comparable prior-year period, indicating limited near-term commercial revenue generation.
Decline in Other Income
Other income, net was approximately $65K for the quarter versus $169K in the prior-year period, a decrease of about $104K (~61.5%), reflecting lower investment income and foreign currency gains.
One-Time / Extraordinary Expenses
Management disclosed over $2M of one-time/extraordinary expenses in the prior quarter (Q4 FY2025) and expects operating expense comparisons to normalize; near-term quarters may still reflect elevated spend while advancing programs.
Remaining Funding Uncertainty from Warrants
While Series J warrants could provide up to an additional $18.2M upon exercise, exercise is not assured; there is therefore residual uncertainty around future dilution and additional funding from warrant conversions.
Clinical and Competitive Risks
Clinical differentiation (tolerability vs GI side effects and reduced hyperpigmentation) and safety/tolerability in target populations (e.g., Prader-Willi) remain to be demonstrated in the clinic. The obesity/weight-loss market is highly competitive — combination strategies with GLP-1s may be required and the company will need to show clear advantages.
Company Guidance
Management provided program and financial guidance to advance its melanocortin‑4 receptor obesity portfolio with IND submission and initiation of a Phase I SAD/MAD for the oral small molecule PL‑7737 in H1 calendar 2026 (Phase I readout by year‑end 2026), a once‑weekly peptide IND planned in H2 2026 (peptide Phase I readout in H1 2027) and subsequent HO and Prader‑Willi Phase II/II‑III trials not to start before mid‑2027; financially, Palatin closed an upsized $18.2M public offering on Nov 12, 2025 (≈2.8M shares/prefunded warrants at $6.50, net proceeds ≈$16.9M, Series J warrants exercisable at $6.50 and expiring the earlier of 18 months or 31 days after FDA IND acceptance, Series K warrants exercisable at $8.125 with a 5‑year term), noted potential additional proceeds up to $18.2M if Series J exercised, received ≈$3.8M upfront from the PL9643 sublicensing (non‑cash debt cancellation to be recognized as license revenue in the quarter ending Mar 31, 2026), reported Q2 FY2026 revenue of $116k, total operating expenses of $7.4M (vs $2.6M prior year), other income net of ~$65k, net cash used in operations of $4.8M, net loss of $7.3M or $2.86/share (vs $2.4M or $5.92/share prior year), cash and cash equivalents of $14.5M as of Dec 31, 2025 (vs $1.3M at Sep 30, 2025 and $2.6M at Jun 30, 2025) with a cash runway expected to extend beyond the quarter ending Mar 31, 2027, and management noted >$2M of one‑time items in a prior quarter and expects roughly $2.5M lower OpEx going forward.Palatin Technologies Financial Statement Overview
Summary
Strong reported gross margin and very low debt reduce balance-sheet risk, but the company remains meaningfully unprofitable with persistent cash burn (TTM operating/free cash flow about -$15.9M) and a volatile/limited revenue base, implying ongoing external funding and dilution risk.Income Statement
TTM (Trailing-Twelve-Months) revenue is ~$8.8M with extremely high gross margin (~99%), but profitability remains deeply negative (net margin ~-109%) as operating costs far exceed the revenue base. Annual results show a sharp swing from $0 revenue in 2025 (annual) to ~$4.5M in 2024 and ~$4.9M in 2023, highlighting a volatile and non-linear revenue profile typical of smaller biotech royalty/milestone streams. Losses have improved versus the very large negative margins seen in 2022–2024, but the company is still meaningfully unprofitable and relies on future revenue expansion or cost reductions to narrow losses.18
Very Negative
Balance Sheet
Leverage is low on the latest period (TTM total debt ~$0.35M and debt-to-equity ~0.03), which reduces financial risk versus highly levered peers. However, equity has been unstable across annual periods (negative equity in 2023–2025 annual), implying past accumulated losses and/or capital structure changes; this can constrain financing flexibility and increase dilution risk. Returns remain weak (TTM return on equity is deeply negative), consistent with ongoing net losses despite modest debt.42
Neutral
Cash Flow
Cash burn is significant: TTM operating cash flow is about -$15.9M and free cash flow is about -$15.9M, indicating the business is not close to self-funding. Cash outflows have persisted for multiple years (annual operating cash flow roughly -$21M to -$31M), and TTM free cash flow declined versus the prior period (negative growth). While free cash flow is broadly in line with net losses (reflecting loss-driven burn rather than major non-cash support), the magnitude and persistence of negative cash generation elevates funding and dilution risk.14
Very Negative
| Breakdown | TTM | Jun 2025 | Sep 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.96M | 0.00 | 4.49M | 4.85M | 1.47M | -188.60K |
| Gross Profit | 8.90M | -258.92K | 4.39M | 4.44M | 1.25M | -336.44K |
| EBITDA | -9.56M | -17.03M | -29.38M | -28.40M | -35.68M | -33.52M |
| Net Income | -9.63M | -17.31M | -29.74M | -24.04M | -36.20M | -33.57M |
Balance Sheet | ||||||
| Total Assets | 17.93M | 3.27M | 10.74M | 17.94M | 36.07M | 67.30M |
| Cash, Cash Equivalents and Short-Term Investments | 14.48M | 2.56M | 9.53M | 10.98M | 29.94M | 60.10M |
| Total Debt | 348.79K | 163.78K | 590.34K | 1.05M | 1.15M | 1.25M |
| Total Liabilities | 6.46M | 8.04M | 10.85M | 19.92M | 19.80M | 17.65M |
| Stockholders Equity | 11.47M | -4.78M | -111.50K | -1.98M | 16.27M | 49.65M |
Cash Flow | ||||||
| Free Cash Flow | -15.88M | -21.31M | -31.50M | -28.85M | -30.18M | -22.65M |
| Operating Cash Flow | -15.87M | -21.31M | -31.46M | -28.42M | -29.92M | -22.65M |
| Investing Cash Flow | 617.18K | 3.13M | 12.45M | -3.43M | -261.37K | -5.72K |
| Financing Cash Flow | 26.31M | 11.21M | 20.55M | 9.90M | 18.36K | -93.64K |
Palatin Technologies Technical Analysis
Positive
16.05
Price Trends
18.82
Positive
16.91
Positive
12.52
Positive
Market Momentum
1.23
Positive
59.74
Neutral
62.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PTN, the sentiment is Positive. The current price of 16.05 is below the 20-day moving average (MA) of 22.03, below the 50-day MA of 18.82, and above the 200-day MA of 12.52, indicating a bullish trend. The MACD of 1.23 indicates Positive momentum. The RSI at 59.74 is Neutral, neither overbought nor oversold. The STOCH value of 62.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PTN.
Palatin Technologies Risk Analysis
Palatin Technologies disclosed 48 risk factors in its most recent earnings report. Palatin Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Palatin Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $13.94M | -1.29 | -107.58% | ― | ― | 83.95% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $75.65M | -5.32 | -71.26% | ― | 185.71% | 79.03% | |
51 Neutral | $6.98M | -1.12 | -71.27% | ― | -72.15% | -223.62% | |
49 Neutral | $38.07M | -0.51 | -5515.09% | ― | 271.10% | 87.20% | |
44 Neutral | $4.95M | -1.09 | -207.73% | ― | 1.70% | -111.67% | |
41 Neutral | $8.91M | -0.31 | -97.58% | ― | -46.88% | 34.83% |
* Healthcare Sector Average
PTN
Palatin Technologies
21.48
-18.66
-46.49%
IBIO
Ibio
2.19
-2.20
-50.11%
PHIO
Phio Pharmaceuticals
1.20
-0.15
-11.11%
BRTX
BioRestorative Therapies
0.23
-1.42
-86.18%
ADXN
Addex Therapeutics
5.90
-1.65
-21.85%
BOLT
Bolt Biotherapeutics
4.64
-3.67
-44.16%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.